Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to improve affordability and access to these agents.

In this podcast, you will hear from Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, who discusses the importance of lymphodepletion in CAR-T therapy, Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who updates us on ICAHT, and Gérard de Pouvourville, PhD, ESSEC Business School, Cergy, France, who shares his thoughts on the cost effectiveness of these agents.

The post Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy appeared first on VJHemOnc.